Selective Disruption of MMP-2 Gene Exacerbates Myocardial Inflammation and Dysfunction in Mice with Cytokine-induced Cardiomyopathy
Overview
Physiology
Authors
Affiliations
Tumor necrosis factor-alpha (TNF-alpha) plays a pathophysiological role in the development and progression of heart failure. Matrix metalloproteinase (MMP)-2 is involved in extracellular matrix remodeling. Recent evidence suggests a protective role for this protease against tissue inflammation. Although MMP-2 is upregulated in the failing heart, little is known about its pathophysiological role. We thus hypothesized that ablation of the MMP-2 gene could affect cardiac remodeling and failure in TNF-alpha-induced cardiomyopathy. We crossed transgenic mice with cardiac-specific overexpression of TNF-alpha (TG) with MMP-2 knockout (KO) mice. Four groups of male and female mice were studied: wild-type (WT) with wild MMP-2 (WT/MMP(+/+)), WT with MMP-2 KO (WT/MMP(-/-)), TNF-alpha TG with wild MMP-2 (TG/MMP(+/+)), and TG with MMP-2 KO (TG/MMP(-/-)). The upregulation of MMP-2 zymographic activity in TG/MMP(+/+) mice was completely abolished in TG/MMP(-/-) mice, and other MMPs and tissue inhibitors of metalloproteinase were comparable between groups. Survival was shorter for male TG/MMP(-/-) than TG/MMP(+/+) mice. Female TG/MMP(-/-) mice were more severely affected than TG/MMP(+/+) mice with diminished cardiac function. Myocardial TNF-alpha and other proinflammatory cytokines were increased in TG/MMP(+/+) mice, and this increase was similarly observed in TG/MMP(-/-) mice. The extent of myocardial infiltrating cells including macrophages was greater in TG/MMP(-/-) than in TG/MMP(+/+) mice. Selective ablation of the MMP-2 gene reduces survival and exacerbates cardiac failure in association with the increased level of myocardial inflammation. MMP-2 may play a cardioprotective role in the pathogenesis of cytokine-induced cardiomyopathy.
Matrix Metalloproteinase 2 as a Pharmacological Target in Heart Failure.
Goncalves P, Nascimento L, Gerlach R, Rodrigues K, Prado A Pharmaceuticals (Basel). 2022; 15(8).
PMID: 35893744 PMC: 9331741. DOI: 10.3390/ph15080920.
Kato H, Duarte S, Liu D, Busuttil R, Coito A PLoS One. 2015; 10(9):e0137642.
PMID: 26355684 PMC: 4565667. DOI: 10.1371/journal.pone.0137642.
miR-146a targets Fos expression in human cardiac cells.
Palomer X, Capdevila-Busquets E, Botteri G, Davidson M, Rodriguez C, Martinez-Gonzalez J Dis Model Mech. 2015; 8(9):1081-91.
PMID: 26112171 PMC: 4582106. DOI: 10.1242/dmm.020768.
Berry E, Hernandez-Anzaldo S, Ghomashchi F, Lehner R, Murakami M, Gelb M J Am Heart Assoc. 2015; 4(4).
PMID: 25820137 PMC: 4579961. DOI: 10.1161/JAHA.115.001868.
Choi I, Yu K, Kim J, De Guzman E, Weisenberger D, Oghamian S Urology. 2013; 82(1):253.e9-15.
PMID: 23806407 PMC: 3697025. DOI: 10.1016/j.urology.2013.04.010.